Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekter af Lactobacillus Plantarum PS128 hos børn med ASD

14. september 2026 opdateret af: Chang Gung Memorial Hospital

Virkninger af Lactobacillus Plantarum PS128 hos børn med autismespektrumforstyrrelse

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

41

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Taoyuan, Taiwan
        • Chang Gung Memorial Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

7 år til 12 år (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • (1) Age 7 to 12 years old.
  • (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
  • (3) Normal control group: Children without autism spectrum disorder.

Exclusion Criteria:

  • (1) Receiving antibiotics within one month.
  • (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
  • (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
  • (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
  • (5) Those with a history of cancer.
  • (6) Those who are allergic to lactic acid bacteria.
  • (7) Not eligible judged by PI

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PS128

Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.

Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.

Placebo komparator: Placebo

Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.

The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.

Ingen indgriben: Normal control

Normal control group are enrolled by invitation from the age and gender matched healthy children.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Changes of Total Scores of Social Responsiveness Scale
Tidsramme: Baseline, Week 12 and Week 16

Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.

Baseline, Week 12 and Week 16

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Changes of Total Scores of Repetitive Behavior Scale-Revised
Tidsramme: Baseline, Week 12 and Week 16

Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Child Behavior Checklist
Tidsramme: Baseline, Week 12 and Week 16

Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Adaptive Behavior Assessment System
Tidsramme: Baseline, week 12 and Week 16

Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior.

Baseline, week 12 and Week 16
Changes in Accuracy of Frith-Happe Animation
Tidsramme: Baseline, Week 12 and Week 16

A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition.

Baseline, Week 12 and Week 16
Changes in Accuracy of Eyes Task
Tidsramme: Baseline, Week 12 and Week 16

An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.

Baseline, Week 12 and Week 16
Changes of Total Scores of Aberrant Behavior Checklist
Tidsramme: Baseline, Week 12 and Week 16

Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Emotional Dysregulation Inventory
Tidsramme: Baseline, Week 12 and Week 16

Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Tidsramme: Baseline, Week 12 and Week 16

Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress.

Baseline, Week 12 and Week 16
Assessment of Clinical Global Impression-Severity of Illness
Tidsramme: Week 12 and Week 16

The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.

Week 12 and Week 16
Assessment of Patient Global Impression of Change
Tidsramme: Week 12 and Week 16

The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)."

Week 12 and Week 16
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Tidsramme: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota

Baseline and Week 12
MRI T1
Tidsramme: Baseline and Week 12

Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Tidsramme: Baseline and Week 12

Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Diffusion Tensor Imaging (DTI) - FA
Tidsramme: Baseline and Week 12

Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Safety Assessment - Albumin
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl).

Baseline and Week 12
Safety Assessment - Total Protein
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl).

Baseline and Week 12
Safety Assessment - ALP
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALP (135-320 U/L).

Baseline and Week 12
Safety Assessment - Total Bilirubin
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl).

Baseline and Week 12
Safety Assessment - T-Cholesterol
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL).

Baseline and Week 12
Safety Assessment - Uric Acid
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl).

Baseline and Week 12
Safety Assessment - BUN
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl).

Baseline and Week 12
Safety Assessment - Creatinine
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl).

Baseline and Week 12
Safety Assessment - AST
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as AST (13-40 U/L).

Baseline and Week 12
Safety Assessment - ALT
Tidsramme: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALT (7-40 U/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Tidsramme: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Tidsramme: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Tidsramme: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Tidsramme: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Tidsramme: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Tidsramme: Baseline and Week 12

Oxidative stress is assessed via Serotonin (ng/mL).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Tidsramme: Baseline and Week 12

Oxidative stress is assessed via GABA (μmol/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Tidsramme: Baseline and Week 12

Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl).

Baseline and Week 12
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Tidsramme: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota.

Baseline and Week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. juli 2022

Primær færdiggørelse (Faktiske)

3. april 2024

Studieafslutning (Faktiske)

3. april 2024

Datoer for studieregistrering

Først indsendt

14. marts 2022

Først indsendt, der opfyldte QC-kriterier

24. marts 2022

Først opslået (Faktiske)

1. april 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. september 2026

Sidst verificeret

1. februar 2025

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 202101416A3

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .